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Background: Sandoz etanercept (SDZ ETN; GP2015) is an etanercept biosimilar with equivalent efficacy and
comparable safety and immunogenicity to reference etanercept (ETN) in patients with moderate-to-severe
chronic plaque-type psoriasis.
Methods: EQUIRA was a phase III, double-blind study conducted in patients with moderate-to-severe rheumatoid
arthritis and inadequate response to disease-modifying anti-rheumatic drugs. Eligible patients were randomized 1:1
to receive subcutaneous 50mg SDZ ETN or ETN, once-weekly, for 24 weeks. At week 24, patients with at least
moderate EULAR response in the SDZ ETN group continued SDZ ETN treatment, and those in the ETN group were
switched to receive 50mg SDZ ETN, for up to 48 weeks. Patients received concomitant methotrexate at a stable dose
(10–25mg/week) and folic acid (≥ 5mg/week). Equivalence between SDZ ETN and ETN for change from baseline in
disease activity score including 28 joint count C-reactive protein (DAS28-CRP) at week 24 (primary endpoint) and
comparable safety and immunogenicity profile of SDZ ETN and ETN have previously been demonstrated at week 24.
Herein, we present the 48-week results of the study after a single switch from ETN to its biosimilar at week 24.
Results: The least squares mean (standard error) change in DAS28-CRP from baseline up to week 48 was comparable
between “continued SDZ ETN” (− 2.90 [0.12], n = 148) and “switched to SDZ ETN” (− 2.78 [0.13], n = 131) groups. The
proportion of patients achieving EULAR good/moderate responses based on DAS28-erythrocyte sedimentation rate
and ACR20/50/70 response rates were comparable between the two groups. The proportion of patients with at least
one treatment-emergent adverse event was 42.9% in the “continued SDZ ETN” and 38.0% in the “switched to SDZ
ETN” groups. Serious adverse events occurred in 4 patients in each of the two groups. After week 24, none of the
patients in the switched group developed anti-drug antibodies (ADAs), while 4 patients in the continued SDZ ETN
group had single-event, very low titer, non-neutralizing ADAs detected.
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Conclusions: The 48-week results from the EQUIRA study demonstrate that switch from ETN to SDZ ETN in patients
with moderate-to-severe rheumatoid arthritis does not impact the efficacy, safety, or immunogenicity of etanercept.
Trial registration: EudraCT number 2012-002009-23, Registered 19 April 2012—prospectively registered.
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Etanercept, a tumor necrosis factor inhibitor, has been
used successfully for the treatment of multiple immune-
mediated inflammatory diseases including moderate-to-
severe rheumatoid arthritis (RA) [1].
Sandoz etanercept (SDZ ETN; development name
GP2015, Erelzi® [Sandoz Inc., Princeton, NJ 08540]) is an
etanercept biosimilar. Pharmacokinetic equivalence and
comparable safety for SDZ ETN and reference etaner-
cept (ETN; Enbrel® [European Union-authorized]) was
demonstrated in a phase I study in healthy subjects [2].
The phase III EGALITY study demonstrated equivalent
efficacy and comparable safety and immunogenicity of
SDZ ETN and ETN in patients with moderate-to-severe
chronic plaque-type psoriasis [3].
The randomized, double-blind, EQUIRA study de-
monstrated similar efficacy and comparable safety and
immunogenicity profile of SDZ ETN to ETN at week 24
in patients with moderate-to-severe RA who had an in-
adequate response to either conventional synthetic (cs)
and/or biologic (b) disease-modifying anti-rheumatic
drugs (DMARDs) [4]. Herein, we present the 48-week
results from the study on the effects of a single switch
between ETN and SDZ ETN at week 24 on efficacy, safety,
and immunogenicity of etanercept.Methods
Study population
Patients, aged ≥ 18 years, were included if they met the fol-
lowing criteria: (1) RA diagnosed according to the American
College of Rheumatology (ACR) 1987 or ACR/European
League Against Rheumatism (EULAR) 2010 criteria [5] for
≥ 6months before baseline; (2) active disease defined as dis-
ease activity score including 28 joint count (DAS28)-C-re-
active protein (CRP) ≥ 3.2; (3) CRP > 5mg/L or erythrocyte
sedimentation rate (ESR) ≥ 28mm/h; (4) inadequate clinical
response to methotrexate (MTX) at a dose of 10–25mg/
week after optimal dose escalation according to local stan-
dards (those who had failed a csDMARD other than MTX,
and any other csDMARD used in combination with MTX
prior to baseline, were allowed after an appropriate wash-out
period of 4weeks); (5) MTX therapy for ≥ 3months and on
a stable dose for ≥ 28 days prior to baseline; (6) stable dose
of folic acid (≥ 5mg per week) for ≥ 28 days before baseline.The key exclusion criteria included (1) any previous
exposure to ETN; (2) treatment with any other bDMARD
therapy for RA, including tumor necrosis factor (TNF)
inhibitors, anti-CD20, immune-modulator drug(s), other
investigational drug(s), and/or device(s) within 3months or
5 half-lives at the time of enrollment, whichever was longer;
(3) previous use of > 2 bDMARDs (patients in whom
bDMARDs were efficacious but withdrawn because of rea-
sons other than efficacy failure or safety issues were not ex-
cluded); (4) functional status class IV according to the ACR
1991 revised criteria [6]; (5) systemic manifestations of RA,
with the exception of Sjögren’s syndrome; (6) any active in-
flammatory or autoimmune diseases other than RA; and
(7) tuberculosis or latent tuberculosis detected by imaging
and/or by the QuantiFERON®-TB Gold test at screening.Study design
The EQUIRA study was conducted from 27 November
2015 to 12 June 2017 at 83 study centers across 16 coun-
tries (NCT02638259). Eligible patients were randomized
1:1 to self-administer 50mg SDZ ETN or ETN (Enbrel®
[European Union-authorized]), provided as pre-filled sy-
ringes, subcutaneously, once-weekly, for 24 weeks (treat-
ment period 1 [TP1]). At week 24, patients achieving at
least a moderate treatment response according to EULAR
response criteria [7] in the SDZ ETN group continued
SDZ ETN (defined as “continued SDZ ETN” group), and
those in the ETN group were switched to SDZ ETN (de-
fined as “switched to SDZ ETN” group), for up to 48
weeks (TP2). The initial randomization schedule and
blinding have been described previously [4].
This study was conducted in accordance with the eth-
ical principles derived from the Declaration of Helsinki
and International Conference on Harmonization Good
Clinical Practices and in compliance with local regula-
tory requirements. The study protocol was approved by
the Independent Ethics Committee or Institutional Re-
view Board for each center. All patients provided written
informed consent before entering the study.Study assessments
The primary endpoint of the study was the change from
baseline in DAS28-CRP up to week 24. The secondary
endpoints, assessed up to week 24 and week 48 included
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proportion of patients achieving good and moderate
EULAR response based on DAS28-ESR [9]; (iii) pro-
portion of patients achieving an improvement in the
ACR20/50/70 response rates; (iv) physical function
assessed by the health assessment questionnaire dis-
ability index (HAQ-DI) score [10, 11], and proportion of
patients achieving HAQ index in normal range (≤ 0.5);
and (v) impact of fatigue on patients assessed by the
Functional Assessment of Chronic Illness Therapy
(FACIT) fatigue scale [12, 13].
Safety assessments included evaluation of the adverse
events (AEs) as well as the local tolerability of injection
sites of both medications as assessed by the investigator
during the study. Immunogenicity assessment included
analysis of anti-drug antibodies (ADAs) up to 48 weeks
using a validated screening, confirmatory, and titer deter-
mination electrochemiluminescence bridging assay [14].
Statistical analysis
The sample size determination has been described pre-
viously [4]. The TP2 full analysis set (FAS) consisted of all
patients who continued to TP2 and had at least one study
assessment documented in TP2. The TP2 per-protocol set
(PPS) consisted of all patients completing the study until
week 48 without major protocol deviations (major protocol
deviations are listed in Additional file 1: Table S1); patients
who prematurely withdrew from the study were also not
included, although this was not a protocol deviation. The
TP2 safety set (SAF) consisted of all patients who receivedFig. 1 Patient disposition. †The primary reason for not completing screenin
withdrawal of consent (n = 12), adverse event (n = 1), lost to follow-up (n =
eligible for TP2; 2 patients in each treatment group were eligible but did n
TP, treatment periodat least one dose of study treatment during TP2. All efficacy
analyses were performed on the TP2 PPS and repeated on
the TP2 FAS. TP2 SAF was used for the safety summaries
in TP2.
During TP2, the “continued SDZ ETN” group was
compared with the “switched to SDZ ETN” group. A
repeated measures analysis of (co)variance with treat-
ment and time as factors up to week 48 was performed
for DAS28-CRP change from baseline. Change from
baseline in DAS28-CRP was estimated using values
up to week 48 from the same mixed-model repeated
measures analysis used to analyze the primary endpoint.
Results
Patient disposition and baseline characteristics
Of the 376 patients randomized in the study, 353 (SDZ
ETN, n = 181; ETN, n = 172) completed TP1. A total of
341 patients entered TP2, of whom 324 completed TP2
(Fig. 1). The reasons for discontinuation during TP2
were AEs (SDZ ETN, n = 5 [2.9%]; ETN, n = 4 [2.4%])
and withdrawal of patient consent (SDZ ETN, n = 1
[0.6%]; ETN, n = 7 [4.2%]). All patients who entered TP2
were included in the TP2 FAS and TP2 SAF. The TP2
PPS included 279 patients (148 [84.6%] and 131 [78.9%]
patients in the SDZ ETN and ETN groups, respectively).
In the overall population who entered TP2, mean (SD)
age was 53.7 (12.0) years, most (80.4%) patients were in
the 18–64 age category, and majority (82.1%) were
females. The mean (SD) duration of RA was 8.4 (7.6)
years and most (71.3%) patients were categorized asg phase included: inclusion/exclusion criteria not fulfilled (n = 169),
1), and other (n = 8); *Four patients in each treatment group were not
ot enter TP2; ETN, reference etanercept; SDZ ETN, Sandoz etanercept;
Table 1 Baseline demographics and disease characteristics (TP2
full analysis set)
Characteristics Continued
SDZ ETN (n = 175)
Switched to
SDZ ETN (n = 166)
Age (years) 55.1 (10.99) 52.2 (12.84)
Female, n (%) 149 (85.1) 131 (78.9)
Race,a n (%)
Caucasian 169 (96.6) 164 (98.8)
Functional RA status, n (%)
Class I 20 (11.4) 25 (15.1)
Class II 122 (69.7) 121 (72.9)
Class III 33 (18.9) 20 (12.0)
DAS28-CRP 5.42 (0.92) 5.54 (0.78)
DAS28-ESR 6.34 (0.88) 6.42 (0.76)
Tender 28 joint count 14.1 (6.21) 14.5 (5.57)
Swollen 28 joint count 10.6 (5.22) 11.0 (5.39)
C-reactive protein (mg/L) 12.0 (21.63) 11.3 (16.34)
HAQ-DI score 1.45 (0.55) 1.47 (0.56)
FACIT-fatigue score 26.82 (9.55) 25.32 (10.14)
Duration of rheumatoid
arthritis (years)
8.75 (8.22) 8.11 (6.93)
Rheumatoid factor, positive,b n (%) 130 (74.30) 118 (71.10)
Anti-CCP, positive, b n (%) 138 (78.90) 119 (71.70)
Prior therapy,c n (%)
MTX only 53 (30.3) 46 (27.7)
MTX + any DMARDs 68 (38.9) 69 (41.6)
MTX + any anti-TNF 30 (17.1) 28 (16.9)
MTX + any other biologic 24 (13.7) 23 (13.9)
Previous DMARDs used, n (%)
1 53 (30.3) 46 (27.7)
2 69 (39.4) 62 (37.3)
3 34 (19.4) 39 (23.5)
4 or more 19 (10.9) 19 (11.4)
MTX dose (mg/week) 16.0 (4.9) 17.0 (4.7)
Duration of MTX (months) 56.3 (49.9) 59.3 (52.4)
Values are mean (SD) unless stated otherwise
CCP cyclic citrullinated peptide, DAS28-CRP disease activity score 28-joint
count, C-reactive protein, DMARDs disease-modifying anti-rheumatic drugs,
ESR erythrocyte sedimentation rate, ETN reference etanercept, FACIT
Functional Assessment of Chronic Illness Therapy, HAQ-DI Health assessment
questionnaire disability index, MTX methotrexate, RA rheumatoid arthritis,
SDZ ETN Sandoz etanercept, SD standard deviation, TNF tumor necrosis
factor, TP2 treatment period 2
aOther race categories in “continued SDZ ETN” group included Black or
African American (n = 5), and American Indian or Alaska Native (n = 1), and
in “switched to SDZ ETN” group included Asian (n = 1) and American Indian
or Alaska Native (n = 1)
bRheumatoid factor ≤ 10 UI/mL and anti-CCP < 17 U/mL are
considered negative
cPrior therapy strata is arranged according to the hierarchy
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cations other than MTX and folic acid were methylpre-
dnisolone (28.2%), meloxicam (15.2%), and ibuprofen
(7.6%). Patient demographics and baseline characteristics
were well-balanced and comparable between TP2 treat-
ment groups (Table 1).
Efficacy
The primary objective of the study to demonstrate that
therapeutic equivalence between SDZ ETN and ETN
was met, as the 95% confidence interval (CI) for the least
squares mean difference between SDZ ETN and ETN
for change from baseline in DAS28-CRP at week 24 was
contained within the pre-specified equivalence margin of
[− 0.6, 0.6] [4].
Efficacy up to week 48
The least squares mean (SE) DAS28-CRP change from
baseline to week 48 was comparable between “continued
SDZ ETN” (− 2.90 [0.12]) and “switched to SDZ ETN”
(− 2.78 [0.130]) groups (Fig. 2). The proportion of
patients achieving EULAR “good” and “moderate” re-
sponses based on DAS28-ESR was similar between “conti-
nued SDZ ETN” and “switched to SDZ ETN” groups (week
48: “continued SDZ ETN” group vs “switched to SDZ
ETN” group: EULAR good response, 54.4% vs 51.9%;
EULAR moderate response, 41.5% vs 44.2%; Fig. 3). The
proportion of patients achieving ACR20, ACR50, and
ACR70 response was generally comparable between “con-
tinued SDZ ETN” and “switched to SDZ ETN” groups;
ACR50 and ACR70 response rates were numerically higher
in the “switched to SDZ ETN” group at all time-points, but
not clinically relevant (Fig. 4). At week 48, ACR20, ACR50,
and ACR70 response rates were 89.1%, 63.3%, and 36.7%,
respectively, in the “continued SDZ ETN” group and 82.4%,
65.6%, and 42.0% in the “switched to SDZ ETN” group.
At week 48, the mean (SD) change from baseline in
HAQ-DI score was − 0.62 (0.55) in the “continued SDZ
ETN” group and − 0.66 (0.55) in the “switched to SDZ
ETN” group, and the mean (SD) change from baseline in
FACIT-fatigue score was 11.6 (9.7) in the “continued SDZ
ETN” group and 10.6 (9.7) in the “switched to SDZ ETN”
group (Additional file 1: Table S2). The proportion of
patients achieving HAQ-DI in normal range (≤ 0.5) up to
week 48 was comparable between “continued SDZ
ETN” group (34.7%) and “switched to SDZ ETN” group
(39.5%).
Safety during TP2
The median (min, max) duration of exposure to study
drug was similar in both treatment groups (“continued
SDZ ETN”, 162 days [8–174]; “switched to SDZ ETN”,
162 days [1–169]). The proportion of patients with at least
one treatment-emergent AE (TEAE) was comparable inthe “continued SDZ ETN” (n = 75, 42.9%) and “switched to
SDZ ETN” (n = 63, 38.0%) groups. Nasopharyngitis was
the TEAE with highest incidence in the “continued SDZ
ETN” and “switched to SDZ ETN” groups (7.4% vs 5.4%)
followed by upper respiratory tract infection (5.1% vs 5.4%;
Fig. 2 DAS28-CRP change from baseline up to week 48 (TP2 per-protocol set). Analyzed using a repeated measures analysis of (co)variance with
treatment and time as factors up to week 48. TP2 PPS comprised all patients completing the study until week 48 without major protocol
deviations. CRP, C-reactive protein; DAS28, disease activity score including 28 joint count; PPS, per-protocol set; SE, standard error; TP,
treatment period
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reported in the “switched to SDZ ETN” group (3.6%;
Table 2), and all were considered by the investigators to be
treatment-related.
No deaths were reported. The proportion of patients
with at least one serious adverse event (SAE) was low and
comparable between the two treatment groups (n = 4 in
each group): “continued SDZ ETN” group: pneumonia,
salivary gland cyst, tibia fracture and cystitis hemorrhagicFig. 3 EULAR good and moderate responses up to week 48 (TP2 per-proto
+ moderate response; EULAR good response: DAS28 ≤ 3.2 and DAS28 imp
and DAS28 improvement > 0.6 and ≤ 1.2, or DAS28 >3.2 and ≤5.1 and DA
TP2 PPS comprised all patients completing the study until week 48 withou
Rheumatism; PPS, per-protocol set; TP, treatment periodin 1 patient [0.6%] each; “switched to SDZ ETN” group:
osteomyelitis, breast cancer, colon adenoma, cardiac
failure, and acute cholecystitis in 1 patient [0.6%] each.
The SAEs of acute cholecystitis and osteomyelitis reported
in the “switched to SDZ ETN” group were suspected to
be related to the study drug by the investigator.
Treatment-related TEAEs occurred in 23 (13.1%) patients
in the “continued SDZ ETN” group and in 19 (11.4%)
patients in the “switched to SDZ ETN” group. Thecol set). Response rate of at least moderate response = good response
rovement from baseline > 1.2; EULAR moderate response: DAS28 ≤ 3.2
S28 improvement > 0.6 or DAS28 >5.1 but DAS28 improvement > 1.2.
t major protocol deviations. EULAR, European League Against
Fig. 4 ACR20, ACR50, and ACR70 response rates up to week 48 (TP2 per-protocol set). TP2 PPS comprised of all patients completing the study
until week 48 without major protocol deviations. ACR, American College of Rheumatology; PPS, per-protocol set; TP, treatment period
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nasopharyngitis (2.9%) in the “continued SDZ ETN”
group" and injection site reactions (3.6%) in the “switched
to SDZ ETN” group (Table 2).
Four (2.3%) patients in the “continued SDZ ETN” group
(benign breast neoplasm, genitourinary tract neoplasm,Table 2 Any TEAEs and treatment-related TEAEs with a ≥ 2%
incidence in any of the treatment groups (TP2 safety set)
Preferred term Continued SDZ ETN
(n = 175) n (%)
Switched to SDZ ETN
(n = 166) n (%)
TEAEs
Nasopharyngitis 13 (7.4) 9 (5.4)
Upper respiratory tract
infection
9 (5.1) 9 (5.4)
Urinary tract infection 7 (4.0) 2 (1.2)
Alanine aminotransferase
increased
4 (2.3) 6 (3.6)
Injection site reaction 0 6 (3.6)
Headache 0 4 (2.4)
Treatment-related TEAEs
Nasopharyngitis 5 (2.9) 0
Injection site reaction 0 6 (3.6)
A patient with multiple occurrences of event within the same system
organ class or preferred term under one treatment is counted only once.
TEAEs are events started after the first dose of study treatment and before
study discontinuation or 30 days after last dose, whichever occurs later.
Events are listed by descending order of occurrence in the “continued
SDZ ETN” group
Adverse event terms are coded using MedDRA version 19.1
ETN reference etanercept, MedDRA medical dictionary for regulatory
activities, SDZ ETN Sandoz etanercept, TEAE treatment-emergent
adverse eventpneumonia, cystitis hemorrhagic; 1 patient [0.6%] each)
and 4 (2.4%) patients in the “switched to SDZ ETN” group
(breast cancer, injection site reaction and alanine amino-
transferase increase, acute cholecystitis, skin hyper-
pigmentation; 1 patient [0.6%] each) discontinued due
to TEAEs. TEAEs of special interest were reported in
9 (5.1%) patients in the “continued SDZ ETN” group
and 12 (7.2%) in the “switched to SDZ ETN” group
(Additional file 1: Table S3).
Immunogenicity
Over 48weeks, the proportion of ADA positive patients was
small (< 3%) and comparable in the SDZ ETN/continued
SDZ ETN groups and ETN/switched to SDZ ETN groups.
After week 24, none of the patients in the switched group
developed ADAs, while 4 patients in the continued SDZ
ETN group had single-event, very low titer, non-neutralizing
ADAs detected (Additional file 1: Table S4).
Discussion
The advent of biosimilars has increased the possibility for
switching between the reference medicine and its bio-
similars, and this process is being evaluated in several
countries [15–18]. The 48-week results from the EQUIRA
study demonstrates that switching patients from ETN to
SDZ ETN did not impact the efficacy, safety, or immuno-
genicity of etanercept in patients with moderate-to-severe
RA. All efficacy parameters including DAS28-CRP change
from baseline, EULAR good/moderate response rates
based on DAS28-ESR, ACR 20/50/70 response rates and
all other efficacy parameters, assessed up to 48 weeks,
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Although numerical differences between the two groups
were observed in the ACR response rates at week 48, these
differences were not clinically relevant.
Sandoz etanercept was well tolerated, and no new or
unexpected safety signals were detected in this study.
Overall, the incidence of TEAEs and SAEs up to week
48 were comparable between the “continued SDZ ETN”
and “switched to SDZ ETN” treatment groups.
For biosimilars, immunogenicity is an important aspect
for the evaluation of clinical comparability [19]. In this
study, a validated state-of-the-art technique comprising a
high sensitivity and drug tolerance, which enables the
detection of low titer and transient ADAs was used for
the detection of ADAs. A false-positive rate for confir-
matory assay of 1% was applied, as recommended recently
[20], instead of the commonly used 0.1% rate [21].
Previous reports have shown that applying a sensitive as
well as a drug-tolerant assay may lead to a higher reported
incidence of ADA compared with historical data [14].
During TP2, 4 (2.4%) patients in the continued SDZ
ETN group had single event. All the measured ADAs
were of low titer, near the detection limit of the applied
highly sensitive method. The detected ADAs were tran-
sient and non-neutralizing, which is in line with pub-
lished data showing that ETN has low immunogenicity,
and ADAs, if any, appear most prominently at week 4
and disappear afterwards [22]. In addition, the ADAs
detected in this study were not clinically relevant as no
correlation was observed between the immunogenicity
outcome and patients’ efficacy and safety.
The results are consistent with the findings from the
EGALITY study in patients with plaque-type psoriasis,
which also showed that switching between ETN and SDZ
ETN does not have an impact on efficacy, safety, or
immunogenicity of etanercept [23]. In addition, the re-
sults also support data on switching from other clinical
trials in different indications [3, 15, 17, 23]. Future
patient registry studies would help to further confirm
the effect of switching on long-term efficacy, safety, and
immunogenicity.
Conclusions
The 48-week results from the EQUIRA study demon-
strate that switch from ETN to the biosimilar SDZ ETN
in patients with moderate-to-severe RA did not impact
the efficacy, safety, or immunogenicity of a continuous
etanercept therapy.
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